Janux Therapeutics, Inc. (JANX) Tops Q2 EPS by 20c
Tweet
Share
E-mailGet Alerts JANX Hot Sheet
Join SI Premium – FREE
Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q2 EPS of ($0.11), $0.20 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $8.89 million versus the consensus estimate of $772 thousand.
For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- NSA lost access to powerful AI model amid Anthropic dispute - NYT
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
